Avoided and avoidable deaths with the use of COVID-19 convalescent plasma in Italy during the first two years of pandemic

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 12, 2024

Abstract Italy was the first western country to be hit by COVID-19 pandemic and suffered nearly 200,000 deaths so far during four years of pandemic. In March 2020, deployed convalescent plasma (CCP) treat hospitalized patients. Despite this initial effort, proportion patients treated with CCP two (2020-2021) very low (approximately 2% individuals for COVID-19). study, we estimated number actual inpatient lives saved treatment in using national mortality data, reduction data from meta-analyses randomized controlled trials real-world data. We also potential if had been 100% or used 15% 75% outpatients. According these models, usage 2020-2021 between 385-1304 lives, but would have increased 17,751-60,079 inpatients transfused CCP. Similarly, broader (15-75%) outpatients could prevented 21,187-190,689 hospitalizations (desaturating hospitals) 6,144-81,926 deaths. These important implications use future infectious disease emergencies.

Language: Английский

---

Avoided and Avoidable Deaths with the Use of COVID-19 Convalescent Plasma in Italy during the First Two Years of Pandemic

Life, Journal Year: 2024, Volume and Issue: 14(9), P. 1207 - 1207

Published: Sept. 23, 2024

Italy was the first western country to be hit by COVID-19 pandemic and has suffered nearly 200,000 deaths so far during four years of pandemic. In March 2020, deployed convalescent plasma (CCP) treat hospitalized patients. Despite this initial effort, proportion patients treated with CCP two (2020–2021) very low (approximately 2% individuals for COVID-19). study, we estimated number actual inpatient lives saved treatment in using national mortality data, reduction data from meta-analyses randomized controlled trials real-world data. We also potential if had been 100% or used 15% 75% outpatients. According these models, usage 2020–2021 between 385–1304 lives, but would have increased 17,751–60,079 inpatients transfused CCP. Similarly, broader (15–75%) outpatients could prevented 21,187–190,689 hospitalizations (desaturating hospitals) 6144–81,926 deaths. These important implications use future infectious disease emergencies.

Language: Английский

---

Using Passive Antibody Therapies in the Next Pandemic

Current topics in microbiology and immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---

The Safety Profile of COVID-19 Convalescent Plasma

Current topics in microbiology and immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---